The modulation of elevated ERK signaling pathways by multiple ERK inhibitors has demonstrated promising results in the treatment of various diseases such as AD [27], brain injuries [28], PD [29], HD [30] autoimmune disease [31], and ASD [32]. This evidence concerns the gene MAPK1 and Parkinson disease.